Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Maculopathy, Age-Related Clinical Trial

Official title:
Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00211419
Study type	Interventional
Source	Manhattan Eye, Ear & Throat Hospital
Contact
Status	Completed
Phase	Phase 1

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00058994` - An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD	Phase 3
Completed	`NCT00051129` - Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)	Phase 3
Completed	`NCT00417846` - Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)	N/A
Completed	`NCT01024998` - Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)	Phase 1
Recruiting	`NCT00331253` - Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP).	Phase 2